An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia

To evaluate efficacy of BL33 for mild and moderate benign prostatic hyperplasia(BPH).There are trials showing that electroacupuncture on BL33 for mild and moderate BPH is more effective than terazosin. It could reduce the International Prostate Syndrome Score (IPSS) by 6.68±2.84(39.79%),lower urinary symptoms bother of score(BS) and bladder residual urine, and increase maximum urinary flow rate.But the efficacy of BL33 has not been studied. The objective of this study is to evaluate efficacy of BL32 for mild and moderate BPH by comparison with non-acupoint group.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

efficacy here means specific effect(or active ingredient) of the point BL33.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beijing, China, 100053
        • Guang'an Men Hospotal Affiliated to China Academy of Chinese Medical Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • 50-70 years old
  • Mild to moderate BPH evaluated by I-PSS
  • Patients having urinary dysfunction more than 3 months
  • Patients with stable life signs
  • no use of α1 receptor blocker, 5α-reductase inhibitor or traditional Chinese medicine for over 1 week
  • Volunteer to join this research and sign the written informed consent prior to receiving treatment

Exclusion Criteria:

  • Urinary dysfunction caused by gonorrhea or urinary tract infection
  • Oliguria and anuria caused by urinary calculi, prostate cancer, bladder tumor and acute/chronic renal failure
  • Urinary dysfunction caused by neurogenic bladder, bladder neck fibrotic and urethral stricture
  • Failure of invasive therapy for prostatic obstruction
  • Injured local organs, muscle and nerve caused by pelvic operation or historical trauma
  • Upper urinary obstruction and hydrocele combined with damaged renal function due to BPH diagnosed by B-ultrasound
  • Patients who can't stick to treatment because of economic reason, far distance between home and the hospital or difficult walking etc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: acupoint
Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
Other Names:
  • acupuncture
  • electroacupuncture
SHAM_COMPARATOR: non-acupoint
Take the place 2 cun far from BL33 on the outside horizontally as the non-point. Needle on the non-point for 60-80mm with a 45°angle. A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.
For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
Other Names:
  • acupuncture
  • electroacupuncture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of IPSS at the 6th Week Compared With Baseline(Intention to Treat)
Time Frame: baseline and the 6th week
International Prostate Symptom Score (IPSS) Range:0-35(0 is best,35 is worst, ordinal),6 week mean minus baseline mean.And analysis for this outcome measure is based on ITT population.
baseline and the 6th week
Change of International Prostate Symptom Score(IPSS) at the 6th Week Compared With Baseline(Per-protocol).
Time Frame: baseline and the 6th week
International Prostate Symptom Score (IPSS) Range:0-35(0 is best,35 is worst, ordinal),6 week mean minus baseline mean. And analysis for this outcome measure is based on per-protocol population.
baseline and the 6th week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of Bladder Residual Urine at the 6th Week
Time Frame: baseline and the 6th week
Bladder residual urine was used to assess the bladder function, 6 week mean minus baseline mean
baseline and the 6th week
Change of Maximum Urinary Flow Rate(Qmax)at the 6th Week
Time Frame: baseline and the 6th week
Maximum urinary flow rate was used to assess the bladder function, 6 week mean minus baseline mean
baseline and the 6th week
Change of International Prostate Symptom Score (IPSS) at the 18th Week
Time Frame: baseline and the 18th week
International Prostate Symptom Score (IPSS) Range:0-35(0 is best,35 is worst, ordinal),18 week mean minus baseline mean.
baseline and the 18th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2010

Primary Completion (ACTUAL)

March 1, 2012

Study Completion (ACTUAL)

May 1, 2012

Study Registration Dates

First Submitted

October 8, 2010

First Submitted That Met QC Criteria

October 8, 2010

First Posted (ESTIMATE)

October 11, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

May 27, 2013

Last Update Submitted That Met QC Criteria

May 18, 2013

Last Verified

May 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • 2009S208

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Benign Prostatic Hyperplasia (BPH)

Clinical Trials on needle

3
Subscribe